-
Innovation Ranking
NewInnovation Ranking – GF Securities Co Ltd
GF Securities Co Ltd (GF Securities) is a provider of investment banking and capital market services. Its portfolio of business activities includes investment banking, wealth management, trading and institutional client services, and investment management. Investment banking services comprise equity financing, debt financing, financial consulting, and merges and acquisition advisory. It provides investment management services such as asset management, fund management, private equity investments, and alternative investment services. GF Securities provides brokerage services include trading, leasing, and custodian services to institutional...
-
Sector Analysis
NewStretchers and Cots Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Stretchers and Cots Market Report Overview The stretchers and cots market was valued at $1.04 billion in 2023 and will grow at a CAGR of more than 2% during 2023-2033. Stretchers and cots support overall patient care and safety, irrespective of the cause of their hospital visits. They form the equipment base of all healthcare facilities in any country. For any kind of treatment to be successful, the hospital must be equipped with basic supplies such as transport stretchers, emergency...
-
Sector Analysis
NewGeneral Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
General Hospital Supplies Market Report Overview The general hospital supplies market size was $12.7 billion in 2023. Factors such as the solid awareness about ensuring medical facilities will drive the market growth at a CAGR of more than 2% from 2023 to 2033. General hospital supplies support patient care and safety irrespective of the reason they might be visiting the hospital. General hospital supplies form the equipment base of all healthcare facilities in any country. For any kind of treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Cervical Cancer Drug Details: GF-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: GF-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Metastatic Pancreatic Cancer Drug Details: GF-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Solid Tumor Drug Details: GF-101 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: GF-101 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Gallbladder Cancer Drug Details: GF-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Esophageal Cancer Drug Details: GF-101 is under development for...